137,871 Shares in Ocular Therapeutix, Inc. $OCUL Purchased by Cubist Systematic Strategies LLC

Key Points

• Cubist Systematic Strategies LLC acquired 137,871 shares of Ocular Therapeutix, Inc. for approximately $1,011,000, representing 0.09% of the company.
• Insider Peter Kaiser sold 3,011 shares while Pravin Dugel sold 21,494 shares of Ocular Therapeutix, indicating a decrease in their ownership positions.
• Ocular Therapeutix's quarterly earnings showed a loss of ($0.39) EPS, missing estimates, with revenue of $13.46 million, reflecting a 17.7% decline year-over-year.

Cubist Systematic Strategies LLC bought a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 137,871 shares of the biopharmaceutical company's stock, valued at approximately $1,011,000. Cubist Systematic Strategies LLC owned about 0.09% of Ocular Therapeutix as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. GF Fund Management CO. LTD. acquired a new position in Ocular Therapeutix in the fourth quarter valued at $28,000. Brooklyn Investment Group raised its holdings in shares of Ocular Therapeutix by 151.5% during the first quarter. Brooklyn Investment Group now owns 5,238 shares of the biopharmaceutical company's stock valued at $38,000 after purchasing an additional 3,155 shares during the period. GAMMA Investing LLC raised its holdings in shares of Ocular Therapeutix by 6,760.0% during the first quarter. GAMMA Investing LLC now owns 8,232 shares of the biopharmaceutical company's stock valued at $60,000 after purchasing an additional 8,112 shares during the period. Vontobel Holding Ltd. acquired a new position in shares of Ocular Therapeutix during the first quarter valued at about $79,000. Finally, Hsbc Holdings PLC raised its holdings in shares of Ocular Therapeutix by 8.1% during the first quarter. Hsbc Holdings PLC now owns 19,573 shares of the biopharmaceutical company's stock valued at $141,000 after purchasing an additional 1,472 shares during the period. Institutional investors own 59.21% of the company's stock.

Insiders Place Their Bets

In other Ocular Therapeutix news, insider Pravin Dugel sold 21,494 shares of the stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $12.04, for a total value of $258,787.76. Following the sale, the insider directly owned 3,227,244 shares in the company, valued at $38,856,017.76. This represents a 0.66% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Jeffrey S. Heier sold 3,063 shares of the stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $12.04, for a total transaction of $36,878.52. Following the completion of the sale, the insider owned 259,911 shares in the company, valued at $3,129,328.44. This represents a 1.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,519 shares of company stock worth $367,865 in the last three months. 2.30% of the stock is currently owned by corporate insiders.

Ocular Therapeutix Stock Up 0.5%

OCUL stock traded up $0.07 during trading on Friday, reaching $12.84. The stock had a trading volume of 640,730 shares, compared to its average volume of 1,840,522. Ocular Therapeutix, Inc. has a one year low of $5.78 and a one year high of $13.85. The company has a quick ratio of 10.02, a current ratio of 10.10 and a debt-to-equity ratio of 0.23. The company's 50 day moving average is $11.96 and its two-hundred day moving average is $9.19. The company has a market capitalization of $2.23 billion, a price-to-earnings ratio of -10.03 and a beta of 1.50.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.04). The company had revenue of $13.46 million for the quarter, compared to the consensus estimate of $13.12 million. Ocular Therapeutix had a negative net margin of 382.51% and a negative return on equity of 71.92%. The firm's revenue was down 17.7% on a year-over-year basis. During the same period in the prior year, the company earned ($0.26) earnings per share. Equities research analysts forecast that Ocular Therapeutix, Inc. will post -0.98 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Needham & Company LLC upped their price objective on shares of Ocular Therapeutix from $14.00 to $15.00 and gave the company a "buy" rating in a report on Tuesday, August 5th. HC Wainwright reissued a "buy" rating and set a $15.00 target price on shares of Ocular Therapeutix in a research report on Thursday, May 29th. Finally, Scotiabank decreased their target price on shares of Ocular Therapeutix from $22.00 to $20.00 and set a "sector outperform" rating for the company in a research report on Wednesday, August 6th. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, Ocular Therapeutix currently has a consensus rating of "Buy" and a consensus target price of $17.20.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.